Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final... von Siefker-Radtke, Arlene O., Powles, Thomas, Moreno, Victor, Kang, Taek Won, Cicin, Irfan, Girvin, Angela, Akapame, Sydney, Triantos, Spyros, O'Hagan, Anne, Zhu, Wei, Tammaro, Meggan, Loriot, Yohann

Volltext

Abstract CT135: A phase 1b study of palbociclib + nab-paclitaxel in patients (pts) with metastatic adenocarcinoma of the pancreas (PDAC) von Hidalgo, Manuel, Carbonero, Rocio Garcia, Lim, Kian-Huat, Messersmith, Wells, Garrido-Laguna, Ignacio, Borazanci, Erkut, Lowy, Andrew, Rodriguez, Laura Medina, Laheru, Daniel, Huang, Xin, Tammaro, Meggan, Martini, Jean-François, Kudla, Arthur, Kern, Kenneth, Macarulla, Teresa

Volltext

A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas von Hidalgo, Manuel, Garcia-Carbonero, Rocio, Lim, Kian-Huat, Messersmith, Wells A, Garrido-Laguna, Ignacio, Borazanci, Erkut, Lowy, Andrew M, Medina Rodriguez, Laura, Laheru, Daniel, Salvador-Barbero, Beatriz, Malumbres, Marcos, Shields, David J, Grossman, Joseph E, Huang, Xin, Tammaro, Meggan, Martini, Jean-François, Yu, Yanke, Kern, Kenneth, Macarulla, Teresa

Volltext